VaxInnate snags $53m under BARDA contract extension
This article was originally published in Scrip
Executive Summary
US biotech VaxInnate is gaining an additional $53m under its February 2011 contract with the Biomedical Advanced Research and Development Authority (BARDA) to develop vaccines against influenza.